Clinical trial
Efficacy and Safety of Blinatumomab for Treatment of Refractory Myasthenia Gravis.
NCT06836973 is registered in ClinicalTrials.gov with Da, Yuwei, M.D. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Efficacy and Safety of Blinatumomab for Treatment of Refractory Myasthenia Gravis.
- Lead sponsor
- Da, Yuwei, M.D.
- Phase
- Phase 2/3
- Overall status
- Not yet recruiting
- Start date
- April 1, 2025
- Completion date
- June 30, 2028
- Enrollment
- 2 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.